1 min left

0% read

BioXcel Therapeutics

Analytics

Infrastructure

Software

Analytics Provider

New Haven, Connecticut, USA

Founded 2017

BioXcel Therapeutics Overview

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. BioXcel's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

BioXcel's two most advanced clinical development programs are:

BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of agitation and opioid withdrawal symptoms.
BXCL701, an investigational, orally administered, systemic innate immunity activator in development for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

Frequently Asked Questions About BioXcel Therapeutics

BioXcel Therapeutics is a company in the cryptocurrency and blockchain space. Visit their profile on Crypto News Navigator for details about their services, team, and company background.

BioXcel Therapeutics has been operating since 2017. You can verify their legitimacy through their official website and social media presence.

BioXcel Therapeutics operates in the analytics sector of the cryptocurrency industry. Compare BioXcel Therapeutics with other analytics companies on Crypto News Navigator to evaluate services, features, and reputation before making your decision.

Before using BioXcel Therapeutics, research their track record (operating since 2017), verify their regulatory compliance, read user reviews, and understand their fee structure. Never share your private keys with any service, and start with small amounts until you are comfortable with the platform.

Safety depends on multiple factors including regulatory compliance, security practices, and track record. BioXcel Therapeutics is based in New Haven, Connecticut, USA, has been operating since 2017. Always enable two-factor authentication, use strong passwords, and never store large amounts on any third-party platform.

BioXcel Therapeutics is based in New Haven, Connecticut, USA, North America.

BioXcel Therapeutics was founded in 2017. The company currently has 99 employees.

BioXcel Therapeutics Details

BioXcel Therapeutics Tags

More About BioXcel Therapeutics

Work Model Details

Employees work from physical offices.

Latest from Academy

Gala Whale Wallets Hold More Than Some Central Banks

Gala (GALA) has a problem that no chart pattern or price prediction can capture: three anonymous wallets control roughly forty percent of the token's 47.6 billion circulating supply, a level of concentration that would trip antitrust rules on any regulated equity market. This piece reads the on-chain trail those whales have left - holdings dating back to mid-2022, a Q1 2026 pause in exchange transfers, and a derivatives-led rally in late April - to ask whether they are quietly accumulating or simply waiting to distribute into a thin market. With daily volume near $16.8 million, even a small unwind by these wallets could overwhelm the order book, the same dynamic that made the May 2024 mint exploit so damaging. A new disinflationary burn and a China cross-chain push could offset some of that pressure, but none of it changes the core flaw: the value of GALA, its staking rewards, and every node operator's payout hinge on three private keys.

Katerina KulikovskaMay 24, 2026

8m read

Altcoins

MIOTA

LDO

RUNE

Seven Years of IOTA Data Reveal What Actually Drives Value

IOTA (MIOTA) is a distributed-ledger network now built on the Move-based Rebased architecture, targeting global trade and real-world asset infrastructure. MIOTA traded near $0.058 with a market cap around $258 million, roughly 98% below its December 2017 all-time high of $5.69. Seven years of price data suggest exchange access and custody have driven IOTA value far more consistently than partnership announcements, architecture upgrades, or developer activity. The May 2025 Coordinator removal through the Rebased upgrade brought decentralized consensus and staking near 11.54% APY, yet the price boost faded within weeks. Enterprise deployments like TWIN and ADAPT continue expanding while the market waits for measurable on-chain demand to register.

Mia HallandMay 23, 2026

10m read

Altcoins

THETA

SPX

FARTCOIN

Theta Explorer Shows the Real Network Activity Behind the Hype

Theta (THETA) gives every holder a free, real-time research tool that most never open: its public block explorer. While the market fixates on partnership announcements and price, the explorer quietly logs what actually happens on-chain - validator uptime, transaction throughput, staking concentration, and block production. This guide walks through how to read it: spotting validators that go dark for weeks, watching whether on-chain transaction volume diverges from theta coin price, and checking how concentrated stake really is across enterprise validators like Google, Samsung, Sony, and Binance. With a hard-capped supply of one billion THETA and a market cap depressed near $204.96M, the gap between on-chain usage and exchange-side price is exactly where the explorer earns its keep. The data is public and free. The skill is knowing what you are looking at.

Crypto News NavigatorMay 22, 2026

9m read